ESR1 and breast cancer: The distinct advantages of the targeted polymeric nanoparticles include their specificity for estrogen receptor-positive breast cancer cells, penetration into the hypoxic core of microtumors, controlled drug discharge, and the consequent reduction in cancer cell viability.